Edesa Biotech (EDSA) Payables (2013 - 2026)

Edesa Biotech has disclosed Payables across 14 years of filings, most recently posting $3.9 million for Q2 2026.

• In Q2 2026, Payables rose 481.27% year-over-year to $3.9 million; the TTM figure through Jun 2026 stood at $3.9 million (up 481.27% YoY), while the FY2025 annual figure was $1.1 million, down 40.51% from the prior year.
• Payables came in at $3.9 million for Q2 2026 at Edesa Biotech, up from $756163.0 in the prior quarter.
• In the past five years, Payables ranged from a high of $5.6 million in Q2 2022 to a low of $672674.0 in Q2 2025.
• Average Payables over 5 years is $2.0 million, with a median of $1.8 million recorded in 2024.
• Year-over-year, Payables soared 521.4% in 2022 and plunged 74.11% in 2023.
• Over 5 years, Payables stood at $1.2 million in 2022, then soared by 57.67% to $1.9 million in 2023, then decreased by 0.44% to $1.9 million in 2024, then plunged by 60.21% to $756163.0 in 2025, then soared by 417.09% to $3.9 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $3.9 million in Q2 2026, $756163.0 in Q4 2025, and $1.1 million in Q3 2025.